Retatrutide + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Overweight or Obesity
Conditions
Overweight or Obesity, CKD, Type 2 Diabetes
Trial Timeline
Jul 20, 2023 → Oct 21, 2025
NCT ID
NCT05936151About Retatrutide + Placebo
Retatrutide + Placebo is a phase 2 stage product being developed by Eli Lilly for Overweight or Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT05936151. Target conditions include Overweight or Obesity, CKD, Type 2 Diabetes.
What happened to similar drugs?
1 of 20 similar drugs in Overweight or Obesity were approved
Approved (1) Terminated (0) Active (19)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07232719 | Phase 3 | Recruiting |
| NCT06982846 | Phase 1 | Active |
| NCT07035093 | Phase 3 | Recruiting |
| NCT06859268 | Phase 3 | Active |
| NCT06383390 | Phase 3 | Active |
| NCT06354660 | Phase 3 | Completed |
| NCT06297603 | Phase 3 | Active |
| NCT05931367 | Phase 3 | Completed |
| NCT05936151 | Phase 2 | Completed |
| NCT05929079 | Phase 3 | Active |
| NCT05929066 | Phase 3 | Active |
| NCT05882045 | Phase 3 | Active |
Competing Products
20 competing products in Overweight or Obesity